Angela Mislowsky

Chemosensitivity Predicted by BluePrint 80-Gene Functional Subtype and MammaPrint in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST)

Pat W. Whitworth, Lisette Stork‐Sloots, Femke A. de Snoo et al. · Annals of Surgical Oncology · 2014 · 89 citations · Full text

Medicine, Endocrinology, Oncology +15

Chemosensitivity and Endocrine Sensitivity in Clinical Luminal Breast Cancer Patients in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) Predicted by Molecular Subtyping

Pat W. Whitworth, Peter D. Beitsch, Angela Mislowsky et al. · Annals of Surgical Oncology · 2016 · 85 citations · Full text

Medicine, Cancer Biology, Oncology +16

Active Monitoring With or Without Endocrine Therapy for Low-Risk Ductal Carcinoma In Situ

E. Shelley Hwang, Terry Hyslop, Thomas Lynch et al. · JAMA · 2024 · 69 citations · Full text

Medicine, Oncology, Surgery +17

Pertuzumab/Trastuzumab/CT Versus Trastuzumab/CT Therapy for HER2+ Breast Cancer: Results from the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST)

Peter D. Beitsch, Pat W. Whitworth, Paul L. Baron et al. · Annals of Surgical Oncology · 2017 · 43 citations

Medicine, Oncology, Pharmacotherapy +14

Impact of Tumor Size on Probability of Pathologic Complete Response After Neoadjuvant Chemotherapy

Paul L. Baron, Peter D. Beitsch, Danielle Boselli et al. · Annals of Surgical Oncology · 2015 · 31 citations · Full text

Medicine, Oncology, Breast Oncology +15